NCT02796170View on ClinicalTrials.gov

Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

August 31, 2019

Study Completion Date

August 31, 2020

Conditions
Type 2 DiabetesHypertension
Interventions
DRUG

Dapagliflozin

5mg pill taken once daily

DRUG

Placebo

5mg pill taken once daily- placebo of Dapagliflozin

Trial Locations (1)

70112

Tulane University, New Orleans

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Tulane University School of Medicine

OTHER